EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 4.0

Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases

Matthew Tennant iD, Chris Frampton, Roger Mulder iD, Ben Beaglehole iD

BJPsych Open · 2023-11 · 9 (6)

DOI: 10.1192/bjo.2023.592 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift BJPsych Open, online erschienen am 26.10.2023. Verfasst von Matthew Tennant und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychological Medicine, University of Otago, Christchurch, New Zealand. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is insufficient evidence to support the pharmacological treatment of borderline personality disorder. However, previous out-patient cohorts have described high rates of polypharmacy in this group. So far, there have been no national studies that have considered polypharmacy in borderline personality disorder.

Aims

To describe psychotropic polypharmacy in people with borderline personality disorder in New Zealand.

Method

New Zealand's national databases have been used to link psychotropic medication dispensing data and diagnostic data for borderline personality disorder. Annual dispensing data for 2014 and 2019 have been compared.

Results

Fifty percent of people with borderline personality disorder who were dispensed medications had three or more psychotropic medications in 2014. This increased to 55.9% in 2019 ( P < 0.001). Those on seven or more psychotropics increased from 8.4 to 10.7% ( P < 0.023). Quetiapine was the most dispensed psychotropic medication, being given to 53.8% of people dispensed medication with borderline personality disorder in 2019. Lorazepam dispensing showed the largest increase, going from 15.5 to 26.7% between 2014 and 2019 ( P < 0.001).

Conclusions

There is a large burden of psychotropic polypharmacy in people with borderline personality disorder. This is concerning because of the lack of evidence regarding the efficacy of these medications in this group.

Schlagwörter

Stichwörter der Autor:innen

Borderline personality disorderantidepressantsantipsychoticscomorbiditypolypharmacy

Autor:innen und Institutionen

  • Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.

ORCID-Profile: Matthew Tennant, Roger Mulder, Ben Beaglehole

Zitieren

APA

Tennant, M., Frampton, C., Mulder, R., & Beaglehole, B. (2023). Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases. BJPsych Open, 9(6). https://doi.org/10.1192/bjo.2023.592

Vancouver

Tennant M, Frampton C, Mulder R, Beaglehole B. Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases. BJPsych Open. 2023;9(6). doi:10.1192/bjo.2023.592

BibTeX
@article{Tennant2023,
  author = {Tennant, Matthew and Frampton, Chris and Mulder, Roger and Beaglehole, Ben},
  title = {Polypharmacy in the treatment of people diagnosed with borderline personality disorder: repeated cross-sectional study using New Zealand's national databases},
  journal = {BJPsych Open},
  year = {2023},
  volume = {9},
  number = {6},
  doi = {10.1192/bjo.2023.592}
}
Kostenlos starten →